NASDAQ:PMVP PMV Pharmaceuticals Q3 2026 Earnings Results & Report $1.20 -0.05 (-4.32%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. PMV Pharmaceuticals missed analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.52 versus the -$0.3367 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market OpensConference Call8:00 AM ET PMV Pharmaceuticals EPS ResultsActual EPS-$0.52Consensus EPS -$0.3367Beat/MissMissed by -$0.1833One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersPMV Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) PMV Pharmaceuticals Q3 2026 Earnings FAQ Did PMV Pharmaceuticals beat earnings estimates for Q3 2026? PMV Pharmaceuticals (NASDAQ:PMVP) reported earnings of -$0.52 per share for Q3 2026, missing the consensus estimate of -$0.3367. The report was announced on Tuesday, November 10, 2026. PMV Pharmaceuticals Earnings HeadlinesPMV Pharmaceuticals (PMVP) Projected to Release Earnings on WednesdayNovember 10 at 2:57 AM | americanbankingnews.comPMV Pharmaceuticals (NASDAQ:PMVP) Cut to Sell at Wall Street ZenNovember 8 at 1:07 AM | americanbankingnews.comMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 10 at 1:00 AM | Behind the Markets (Ad)Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026November 4, 2026 | globenewswire.comPMV Pharmaceuticals (NASDAQ:PMVP) Raised to "Hold" at Wall Street ZenNovember 2, 2026 | americanbankingnews.comPMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer OpportunityOctober 7, 2026 | seekingalpha.comSee More PMV Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email. Email Address About PMV PharmaceuticalsPMV Pharmaceuticals (NASDAQ:PMVP) is a clinical-stage precision oncology company focused on developing therapies that target cancer-causing mutations in the tumor suppressor protein p53. The company aims to discover and develop small-molecule medicines designed to restore the normal tumor-suppressing function of mutant p53 proteins. PMV’s lead product candidate is rezatapopt, also known as PC14586, an investigational oral therapy designed to selectively target the p53 Y220C mutation. This mutation occurs in a range of solid tumors, and rezatapopt is being evaluated for its potential to reactivate the altered p53 protein and inhibit cancer-cell growth. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals is advancing rezatapopt through clinical development in patients with advanced solid tumors containing the p53 Y220C mutation. The company’s programs are intended for patients identified through molecular testing, supporting a precision-medicine approach to cancer treatment.View PMV Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
